ELITE UNIVERSAL TEST
BANK: Women’s Health
Primary Care Clinical
Guide (5th Edition)
PART 0: THE NAVIGATOR
● Tier 1 (Questions 1–29) - Foundational Syntax & Application: Testing "Hard Deck"
definitions, core formulas, and primary clinical theories through realistic scenarios.
● Tier 2 (Questions 30–58) - Complex Application & Simulation: Situation-dependent
variables, cross-referencing contraindications, and immediate algorithmic actions.
● Tier 3 (Questions 59–88) - Grandmaster Synthesis: Paragraph-long, high-stakes
scenarios requiring the synthesis of multiple, competing concepts to solve a complex
problem or avert a failure.
PART I: THE PRIMER
Mastering this exhaustive test bank translates directly to elite clinical performance by replacing
rote memorization with a synthesized understanding of complex pathophysiological and
pharmacological systems in women's health. The analysis indicates that rigorous adherence to
2026/2027 global standards drastically reduces maternal-fetal morbidity, optimizes menopausal
transitions, and prevents systemic clinical errors.
The "Critical Axioms" Cheat Sheet
Clinical Domain 2026/2027 Global Legacy/Outdated Diagnostic /
Standard Protocol Therapeutic Imperative
Cervical Cancer Primary hrHPV testing Annual Pap cytology Self-collection mitigates
Screening every 5 years; patient testing for average-risk structural access
self-collection is a cohorts. barriers and reduces
validated option (ages clinical attrition.
30–65).
Breast Cancer Biennial mammography Individualized Early initiation mitigates
Screening strictly initiated at age screening initiation rising incidence in the
40 for average-risk delayed until age 50. 40–49 demographic;
populations. supplemental imaging
for dense breasts
,Clinical Domain 2026/2027 Global Legacy/Outdated Diagnostic /
Standard Protocol Therapeutic Imperative
remains highly
individualized.
Endometriosis Clinical diagnosis via Mandatory diagnostic Delays in surgical
Management symptom clustering and laparoscopy prior to diagnosis historically
Transvaginal definitive diagnosis and compounded disease
Ultrasound (TVUS); treatment. burden; early empiric
immediate empiric suppression preserves
medical therapy. function.
Bacterial STI Doxy PEP: 200mg Reactive antibiotic Prophylactic
Prophylaxis doxycycline administration only intervention
administered within 72 post-symptom fundamentally disrupts
hours of unprotected presentation or positive bacterial replication
sexual contact for testing. cascades in highly
high-risk populations. exposed cohorts.
Menopausal Hormone HT initiated in patients Blanket avoidance of all Transdermal
Therapy (HT) <60 years of age or systemic estrogen due formulations mitigate
<10 years to misinterpretations of VTE risk; compounded
post-menopause for early WHI data. bioidenticals lack
vasomotor symptoms regulatory safety
(VMS). profiles and remain
contraindicated.
AUB Diagnostics FIGO PALM-COEIN Vague terminology Structural lesions
classification such as "menorrhagia" require
separating structural or "dysfunctional surgical/targeted
(PALM) from uterine bleeding". therapy; non-structural
non-structural (COEIN) etiologies necessitate
etiologies. endocrine/hematologic
correction.
PART II: THE ELITE TEST BANK
Tier 1 - Foundational Syntax & Application
Q1: Under 2026 USPSTF guidelines, which screening protocol is MOST ACCURATE for an
average-risk 42-year-old female presenting for a well-woman exam? A) Annual mammography
starting immediately. B) Biennial mammography starting immediately. C) Defer mammography
until age 50 based on shared decision-making. D) Annual breast MRI due to high breast density.
● The Answer: B (Biennial mammography starting immediately.)
● Distractor Analysis:
○ A is incorrect: The USPSTF explicitly recommends biennial, not annual, screening
to balance early detection with the risk of overdiagnosis.
○ C is incorrect: Deferring to 50 is a legacy guideline; the 2024/2026 update
mandates starting at 40.
○ D is incorrect: Current evidence remains insufficient to mandate supplemental MRI
based exclusively on dense breast tissue in an average-risk patient.
The Mentor's Analysis: The 2026 USPSTF mandate unequivocally lowers the baseline breast
,cancer screening age to 40 for average-risk women on a biennial schedule. When facing
screening decisions, the immediate priority is adhering to updated age stratifications to prevent
delayed diagnoses. By utilizing the 40-year baseline, clinicians bypass the common trap of
waiting until age 50. Professional Intuition: Forty is the new fifty; never delay
mammography based on outdated legacy parameters.
Q2: A 34-year-old average-risk female requests cervical cancer screening. Per 2026
HRSA/USPSTF updates, the MOST APPROPRIATE primary screening modality is: A) Annual
Pap smear with cytology. B) Co-testing with Pap and hrHPV every 3 years. C) Primary hrHPV
testing, which may include patient self-collection. D) Colposcopy with targeted endometrial
biopsy.
● The Answer: C (Primary hrHPV testing, which may include patient self-collection.)
● Distractor Analysis:
○ A is incorrect: Annual cytology represents outdated, low-value care for average-risk
women.
○ B is incorrect: While 5-year co-testing is acceptable, 3-year co-testing is off-cycle;
primary hrHPV every 5 years is the preferred standard.
○ D is incorrect: Colposcopy is a secondary diagnostic procedure for abnormal
results, not a primary screen.
The Mentor's Analysis: Innovation in screening compliance relies on reducing barriers. When
facing high screening attrition rates, the immediate priority is offering accessible modalities. By
utilizing self-collected hrHPV testing, practitioners bypass the common trap of enforcing
uncomfortable speculum exams on hesitant patients. Professional Intuition: Empower
average-risk patients with self-collection options to drastically improve population-level
screening compliance.
Q3: A 28-year-old presents with heavy menstrual bleeding. Ultrasound reveals a 4cm
submucosal fibroid. Using the FIGO classification, this etiology is categorized as: A) AUB-O B)
AUB-L C) AUB-E D) AUB-A
● The Answer: B (AUB-L)
● Distractor Analysis:
○ A is incorrect: Ovulatory dysfunction is non-structural and part of the COEIN arm.
○ C is incorrect: Endometrial factors represent microscopic dysfunction, not
macroscopic tumors.
○ D is incorrect: Adenomyosis involves endometrial glands trapped in the
myometrium, not a discrete leiomyoma.
The Mentor's Analysis: The PALM-COEIN system bifurcates abnormal uterine bleeding into
structural (PALM) and non-structural (COEIN) origins. When facing undifferentiated AUB, the
immediate priority is ultrasound evaluation. By utilizing precise anatomical categorization,
providers bypass the common trap of using outdated terms like "menorrhagia." Professional
Intuition: If the lesion can be visualized anatomically on standard imaging, it belongs in
the PALM category.
Q4: According to 2026 ACOG Endometriosis Guidelines, what is the FIRST diagnostic step for a
24-year-old presenting with chronic cyclic pelvic pain and deep dyspareunia? A) Immediate
diagnostic laparoscopy to histologically confirm implants. B) Serum CA-125 biomarker testing.
C) Clinical diagnosis based on symptoms and Transvaginal Ultrasound (TVUS). D) Routine
pelvic MRI without prior ultrasound.
● The Answer: C (Clinical diagnosis based on symptoms and Transvaginal Ultrasound
(TVUS).)
● Distractor Analysis:
, ○ A is incorrect: The 2026 update strictly removes the requirement for surgical
diagnosis prior to initiating empiric medical treatment.
○ B is incorrect: Biomarkers like CA-125 are strongly advised against due to poor
specificity in endometriosis.
○ D is incorrect: MRI is reserved for complex surgical mapping of deep infiltrating
disease, not first-line primary care evaluation.
The Mentor's Analysis: Clinical symptom clusters paired with TVUS provide sufficient diagnostic
certainty. When facing chronic pelvic pain, the immediate priority is initiating non-invasive
empiric therapy. By utilizing clinical diagnosis, practitioners bypass the common trap of inflicting
diagnostic delays averaging 4 to 11 years. Professional Intuition: Treat the symptom cluster
empirically; do not let the absence of surgical validation delay patient relief.
Q5: A 54-year-old female presents with severe vasomotor symptoms (VMS). She had a total
hysterectomy at age 45 for benign fibroids. Based on NAMS 2025 guidelines, the MOST
APPROPRIATE systemic hormone therapy (HT) is: A) Combined Estrogen-Progestin Therapy
(EPT) orally. B) Systemic Estrogen Therapy (ET) alone. C) Compounded bioidentical hormone
pellets. D) Vaginal estrogen cream exclusively.
● The Answer: B (Systemic Estrogen Therapy (ET) alone.)
● Distractor Analysis:
○ A is incorrect: Progestin is strictly required for endometrial protection; a patient
without a uterus does not need it, and unnecessary addition increases breast
cancer risk.
○ C is incorrect: NAMS explicitly warns against compounded bioidenticals due to lack
of FDA regulation, sterility issues, and erratic dosing.
○ D is incorrect: Vaginal estrogen targets Genitourinary Syndrome of Menopause
(GSM), not systemic vasomotor symptoms.
The Mentor's Analysis: Systemic estrogen is the gold standard for VMS, but unopposed
estrogen causes endometrial cancer. When facing a hysterectomized patient, the immediate
priority is providing ET without unnecessary progestins. By utilizing ET alone, the provider
bypasses the common trap of exposing the patient to dual-hormone adverse effects.
Professional Intuition: Uterus present = Estrogen + Progestin. Uterus absent = Estrogen
alone.
Q6: A 22-year-old high-risk patient requests CDC-recommended Doxycycline Post-Exposure
Prophylaxis (Doxy PEP) after condomless sex. What is the EXACT prescribed regimen? A)
100mg daily for 7 days. B) 200mg within 72 hours of unprotected sex. C) 500mg single dose
intramuscularly. D) 200mg daily for 28 days.
● The Answer: B (200mg within 72 hours of unprotected sex.)
● Distractor Analysis:
○ A is incorrect: This is the therapeutic regimen for active Chlamydia infection, not
prophylaxis.
○ C is incorrect: This mirrors the legacy Ceftriaxone dose for active Gonorrhea.
○ D is incorrect: This mimics HIV PEP duration, which is biochemically irrelevant for
bacterial STIs.
The Mentor's Analysis: Doxy PEP is a targeted, event-driven pharmacological intervention to
abort bacterial replication before clinical infection establishes. When facing bacterial STI
exposure, the immediate priority is rapid antibiotic deployment. By utilizing the 72-hour window,
patients bypass the common trap of waiting for symptoms to appear. Professional Intuition:
Doxy PEP's efficacy rapidly decays after 72 hours; timely administration is the sole
determinant of prophylactic success.
BANK: Women’s Health
Primary Care Clinical
Guide (5th Edition)
PART 0: THE NAVIGATOR
● Tier 1 (Questions 1–29) - Foundational Syntax & Application: Testing "Hard Deck"
definitions, core formulas, and primary clinical theories through realistic scenarios.
● Tier 2 (Questions 30–58) - Complex Application & Simulation: Situation-dependent
variables, cross-referencing contraindications, and immediate algorithmic actions.
● Tier 3 (Questions 59–88) - Grandmaster Synthesis: Paragraph-long, high-stakes
scenarios requiring the synthesis of multiple, competing concepts to solve a complex
problem or avert a failure.
PART I: THE PRIMER
Mastering this exhaustive test bank translates directly to elite clinical performance by replacing
rote memorization with a synthesized understanding of complex pathophysiological and
pharmacological systems in women's health. The analysis indicates that rigorous adherence to
2026/2027 global standards drastically reduces maternal-fetal morbidity, optimizes menopausal
transitions, and prevents systemic clinical errors.
The "Critical Axioms" Cheat Sheet
Clinical Domain 2026/2027 Global Legacy/Outdated Diagnostic /
Standard Protocol Therapeutic Imperative
Cervical Cancer Primary hrHPV testing Annual Pap cytology Self-collection mitigates
Screening every 5 years; patient testing for average-risk structural access
self-collection is a cohorts. barriers and reduces
validated option (ages clinical attrition.
30–65).
Breast Cancer Biennial mammography Individualized Early initiation mitigates
Screening strictly initiated at age screening initiation rising incidence in the
40 for average-risk delayed until age 50. 40–49 demographic;
populations. supplemental imaging
for dense breasts
,Clinical Domain 2026/2027 Global Legacy/Outdated Diagnostic /
Standard Protocol Therapeutic Imperative
remains highly
individualized.
Endometriosis Clinical diagnosis via Mandatory diagnostic Delays in surgical
Management symptom clustering and laparoscopy prior to diagnosis historically
Transvaginal definitive diagnosis and compounded disease
Ultrasound (TVUS); treatment. burden; early empiric
immediate empiric suppression preserves
medical therapy. function.
Bacterial STI Doxy PEP: 200mg Reactive antibiotic Prophylactic
Prophylaxis doxycycline administration only intervention
administered within 72 post-symptom fundamentally disrupts
hours of unprotected presentation or positive bacterial replication
sexual contact for testing. cascades in highly
high-risk populations. exposed cohorts.
Menopausal Hormone HT initiated in patients Blanket avoidance of all Transdermal
Therapy (HT) <60 years of age or systemic estrogen due formulations mitigate
<10 years to misinterpretations of VTE risk; compounded
post-menopause for early WHI data. bioidenticals lack
vasomotor symptoms regulatory safety
(VMS). profiles and remain
contraindicated.
AUB Diagnostics FIGO PALM-COEIN Vague terminology Structural lesions
classification such as "menorrhagia" require
separating structural or "dysfunctional surgical/targeted
(PALM) from uterine bleeding". therapy; non-structural
non-structural (COEIN) etiologies necessitate
etiologies. endocrine/hematologic
correction.
PART II: THE ELITE TEST BANK
Tier 1 - Foundational Syntax & Application
Q1: Under 2026 USPSTF guidelines, which screening protocol is MOST ACCURATE for an
average-risk 42-year-old female presenting for a well-woman exam? A) Annual mammography
starting immediately. B) Biennial mammography starting immediately. C) Defer mammography
until age 50 based on shared decision-making. D) Annual breast MRI due to high breast density.
● The Answer: B (Biennial mammography starting immediately.)
● Distractor Analysis:
○ A is incorrect: The USPSTF explicitly recommends biennial, not annual, screening
to balance early detection with the risk of overdiagnosis.
○ C is incorrect: Deferring to 50 is a legacy guideline; the 2024/2026 update
mandates starting at 40.
○ D is incorrect: Current evidence remains insufficient to mandate supplemental MRI
based exclusively on dense breast tissue in an average-risk patient.
The Mentor's Analysis: The 2026 USPSTF mandate unequivocally lowers the baseline breast
,cancer screening age to 40 for average-risk women on a biennial schedule. When facing
screening decisions, the immediate priority is adhering to updated age stratifications to prevent
delayed diagnoses. By utilizing the 40-year baseline, clinicians bypass the common trap of
waiting until age 50. Professional Intuition: Forty is the new fifty; never delay
mammography based on outdated legacy parameters.
Q2: A 34-year-old average-risk female requests cervical cancer screening. Per 2026
HRSA/USPSTF updates, the MOST APPROPRIATE primary screening modality is: A) Annual
Pap smear with cytology. B) Co-testing with Pap and hrHPV every 3 years. C) Primary hrHPV
testing, which may include patient self-collection. D) Colposcopy with targeted endometrial
biopsy.
● The Answer: C (Primary hrHPV testing, which may include patient self-collection.)
● Distractor Analysis:
○ A is incorrect: Annual cytology represents outdated, low-value care for average-risk
women.
○ B is incorrect: While 5-year co-testing is acceptable, 3-year co-testing is off-cycle;
primary hrHPV every 5 years is the preferred standard.
○ D is incorrect: Colposcopy is a secondary diagnostic procedure for abnormal
results, not a primary screen.
The Mentor's Analysis: Innovation in screening compliance relies on reducing barriers. When
facing high screening attrition rates, the immediate priority is offering accessible modalities. By
utilizing self-collected hrHPV testing, practitioners bypass the common trap of enforcing
uncomfortable speculum exams on hesitant patients. Professional Intuition: Empower
average-risk patients with self-collection options to drastically improve population-level
screening compliance.
Q3: A 28-year-old presents with heavy menstrual bleeding. Ultrasound reveals a 4cm
submucosal fibroid. Using the FIGO classification, this etiology is categorized as: A) AUB-O B)
AUB-L C) AUB-E D) AUB-A
● The Answer: B (AUB-L)
● Distractor Analysis:
○ A is incorrect: Ovulatory dysfunction is non-structural and part of the COEIN arm.
○ C is incorrect: Endometrial factors represent microscopic dysfunction, not
macroscopic tumors.
○ D is incorrect: Adenomyosis involves endometrial glands trapped in the
myometrium, not a discrete leiomyoma.
The Mentor's Analysis: The PALM-COEIN system bifurcates abnormal uterine bleeding into
structural (PALM) and non-structural (COEIN) origins. When facing undifferentiated AUB, the
immediate priority is ultrasound evaluation. By utilizing precise anatomical categorization,
providers bypass the common trap of using outdated terms like "menorrhagia." Professional
Intuition: If the lesion can be visualized anatomically on standard imaging, it belongs in
the PALM category.
Q4: According to 2026 ACOG Endometriosis Guidelines, what is the FIRST diagnostic step for a
24-year-old presenting with chronic cyclic pelvic pain and deep dyspareunia? A) Immediate
diagnostic laparoscopy to histologically confirm implants. B) Serum CA-125 biomarker testing.
C) Clinical diagnosis based on symptoms and Transvaginal Ultrasound (TVUS). D) Routine
pelvic MRI without prior ultrasound.
● The Answer: C (Clinical diagnosis based on symptoms and Transvaginal Ultrasound
(TVUS).)
● Distractor Analysis:
, ○ A is incorrect: The 2026 update strictly removes the requirement for surgical
diagnosis prior to initiating empiric medical treatment.
○ B is incorrect: Biomarkers like CA-125 are strongly advised against due to poor
specificity in endometriosis.
○ D is incorrect: MRI is reserved for complex surgical mapping of deep infiltrating
disease, not first-line primary care evaluation.
The Mentor's Analysis: Clinical symptom clusters paired with TVUS provide sufficient diagnostic
certainty. When facing chronic pelvic pain, the immediate priority is initiating non-invasive
empiric therapy. By utilizing clinical diagnosis, practitioners bypass the common trap of inflicting
diagnostic delays averaging 4 to 11 years. Professional Intuition: Treat the symptom cluster
empirically; do not let the absence of surgical validation delay patient relief.
Q5: A 54-year-old female presents with severe vasomotor symptoms (VMS). She had a total
hysterectomy at age 45 for benign fibroids. Based on NAMS 2025 guidelines, the MOST
APPROPRIATE systemic hormone therapy (HT) is: A) Combined Estrogen-Progestin Therapy
(EPT) orally. B) Systemic Estrogen Therapy (ET) alone. C) Compounded bioidentical hormone
pellets. D) Vaginal estrogen cream exclusively.
● The Answer: B (Systemic Estrogen Therapy (ET) alone.)
● Distractor Analysis:
○ A is incorrect: Progestin is strictly required for endometrial protection; a patient
without a uterus does not need it, and unnecessary addition increases breast
cancer risk.
○ C is incorrect: NAMS explicitly warns against compounded bioidenticals due to lack
of FDA regulation, sterility issues, and erratic dosing.
○ D is incorrect: Vaginal estrogen targets Genitourinary Syndrome of Menopause
(GSM), not systemic vasomotor symptoms.
The Mentor's Analysis: Systemic estrogen is the gold standard for VMS, but unopposed
estrogen causes endometrial cancer. When facing a hysterectomized patient, the immediate
priority is providing ET without unnecessary progestins. By utilizing ET alone, the provider
bypasses the common trap of exposing the patient to dual-hormone adverse effects.
Professional Intuition: Uterus present = Estrogen + Progestin. Uterus absent = Estrogen
alone.
Q6: A 22-year-old high-risk patient requests CDC-recommended Doxycycline Post-Exposure
Prophylaxis (Doxy PEP) after condomless sex. What is the EXACT prescribed regimen? A)
100mg daily for 7 days. B) 200mg within 72 hours of unprotected sex. C) 500mg single dose
intramuscularly. D) 200mg daily for 28 days.
● The Answer: B (200mg within 72 hours of unprotected sex.)
● Distractor Analysis:
○ A is incorrect: This is the therapeutic regimen for active Chlamydia infection, not
prophylaxis.
○ C is incorrect: This mirrors the legacy Ceftriaxone dose for active Gonorrhea.
○ D is incorrect: This mimics HIV PEP duration, which is biochemically irrelevant for
bacterial STIs.
The Mentor's Analysis: Doxy PEP is a targeted, event-driven pharmacological intervention to
abort bacterial replication before clinical infection establishes. When facing bacterial STI
exposure, the immediate priority is rapid antibiotic deployment. By utilizing the 72-hour window,
patients bypass the common trap of waiting for symptoms to appear. Professional Intuition:
Doxy PEP's efficacy rapidly decays after 72 hours; timely administration is the sole
determinant of prophylactic success.
